An interview with Dr Jim Phillips, CEO of Midatech plc James Faulkner: Hi Jim and thanks for taking the time to speak to Master Investor. Midatech describes itself as an “international specialty pharmaceutical company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need.” For the benefit…
James Faulkner: Hi Andy. Thanks for taking the time to speak with Master Investor. For the benefit of the uninitiated, please give our readers a brief introduction to Milamber and what it’s all about. Andy Hasoon: Milamber Ventures Plc is listed on ISDX, a stock exchange run by ICAP. We are an incubator and accelerator…
James Faulkner: Thanks for taking the time to speak with Master Investor. Can you begin by giving our readers a bit of background information on PulseFlow and its recent history? Les Lindsay (CEO): PulseFlow Technologies (PFT) is the trading name for The Diabetic Boot Company Ltd (DBC). DBC was founded in February 2010 after we…
As seen in this month’s Master Investor Magazine. James Faulkner: Thank you for taking the time to speak with Master Investor. Please give our readers a brief overview of GB Group, for the benefit of the uninitiated. David Wilson: GB Group, trading as GBG, is a global specialist in Identity Data Intelligence. This means we…
As seen in this month’s Master Investor Magazine. James Faulkner: Thanks for taking the time to speak with Master Investor. To begin with, please introduce yourself, and the company you represent, to our readers. Kobus Paulsen: My name is Kobus Paulsen, and I am founder and chairman of Cognosec. Since 1999 have I have acquired and…
An interview with Martin Warner, Managing Director of Michelmersh Brick Holdings. As featured in this month’s Master Investor Magazine. James Faulkner: Thanks for taking the time to speak to Master Investor. Could you begin by giving our readers a brief overview of Michelmersh Brick Holdings (MBH) and its history for the benefit of the uninitiated?…
As seen in this month’s issue of Master Investor Magazine. Wiley £16.58 on Amazon (Hardback) In his tenth book, investor and Forbes columnist Ken Fisher sets out to lend a helping hand to investors looking to chart a path to prosperity whilst being bombarded by media hype and other ‘noise’ on a daily basis. Beat…
As seen in this month’s issue of Master Investor Magazine. An Interview with Richard Wolanski, Finance Director of Avation. Master Investor: Good morning, Richard, and thanks for taking the time to give our readers an opportunity to get to know Avation (AVAP) better. Could you begin by giving our readers a brief overview of Avation…
As seen in this month’s Master Investor Magazine One of the inherent contradictions within capitalism is its tendency to gravitate towards monopolies. From a capitalist’s perspective, a monopoly is the favoured situation, as it removes the competition and enables supernormal profits to be extracted indefinitely. However, in practice, monopolies tend to be bad for the…
As seen in this month’s Master Investor Magazine Clinigen (CLIN) Clinigen supplies drugs for clinical trials, many of which compare an experimental treatment with one already on the market. It also supplies unlicensed medicines into markets where a drug is being withdrawn or where there is no alternative. In addition to this, it also buys…
